Abstract
Insulin-like growth factor-I (IGF-I) is a naturally occurring single chain polypeptide of 7649 Da that is produced primarily in the liver. The metabolic activities of IGF-I are similar to those of insulin and its effects on growth, development, regeneration and metabolism have been widely studied. Indeed, IGF-I is currently being used clinically for the treatment of growth related disorders and its therapeutic value is also being evaluated in diabetes, IGF-I-induced neuroprotection, and in promoting bone healing. However, like many other peptides, IGF-I has a short biological half-life and is rapidly removed from circulation following systemic administration. In the vascular system, this is normally compensated for by the association of IGF-I with IGF-binding proteins (IGFBPs), that also appear to regulate the activities of IGF-I. Here, we describe the biopharmaceutical properties of different parenteral formulations of IGF-I. The pharmaceutical characteristics of conventional formulations such as aqueous IGF-I solutions are compare with new controlled release formulations such as multivesicular liposomes, osmotic minipumps, and poly (DL-lactic-co-glycolic) acid (PLGA) microspheres.
Keywords: rhIgf-I, activity, pharmacology, therapeutics, pharmacokinetics, bioavailability, parenteral, controlled release
Current Pharmaceutical Biotechnology
Title: Pharmacological Characteristics of Parenteral IGF-I Administration
Volume: 4 Issue: 2
Author(s): J. Torrado and C. Carrascosa
Affiliation:
Keywords: rhIgf-I, activity, pharmacology, therapeutics, pharmacokinetics, bioavailability, parenteral, controlled release
Abstract: Insulin-like growth factor-I (IGF-I) is a naturally occurring single chain polypeptide of 7649 Da that is produced primarily in the liver. The metabolic activities of IGF-I are similar to those of insulin and its effects on growth, development, regeneration and metabolism have been widely studied. Indeed, IGF-I is currently being used clinically for the treatment of growth related disorders and its therapeutic value is also being evaluated in diabetes, IGF-I-induced neuroprotection, and in promoting bone healing. However, like many other peptides, IGF-I has a short biological half-life and is rapidly removed from circulation following systemic administration. In the vascular system, this is normally compensated for by the association of IGF-I with IGF-binding proteins (IGFBPs), that also appear to regulate the activities of IGF-I. Here, we describe the biopharmaceutical properties of different parenteral formulations of IGF-I. The pharmaceutical characteristics of conventional formulations such as aqueous IGF-I solutions are compare with new controlled release formulations such as multivesicular liposomes, osmotic minipumps, and poly (DL-lactic-co-glycolic) acid (PLGA) microspheres.
Export Options
About this article
Cite this article as:
Torrado J. and Carrascosa C., Pharmacological Characteristics of Parenteral IGF-I Administration, Current Pharmaceutical Biotechnology 2003; 4 (2) . https://dx.doi.org/10.2174/1389201033489865
DOI https://dx.doi.org/10.2174/1389201033489865 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Pharmacology of Systemic Analgesics in Neonates
Current Drug Therapy Scope and Limitations of The Co-Drug Approach to Topical Drug Delivery
Current Pharmaceutical Design QT Alterations in Psychopharmacology: Proven Candidates and Suspects
Current Drug Safety Geriatric Psychopharmacology in Acute Settings
Current Psychopharmacology Endothelins and the Role of Endothelin Antagonists in the Management of Posttraumatic Vasospasm
Current Pharmaceutical Design The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Chemistry and Structural Evaluation of Different Phospholipase A2 Inhibitors in Arachidonic Acid Pathway Mediated Inflammation and Snake Venom Toxicity
Current Topics in Medicinal Chemistry The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications
Current Pharmaceutical Design Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Comparative Biochemical Studies of Myotoxic Phospholipase A2 From Bothrops Venom
Protein & Peptide Letters Pharmacological Approaches in the Treatment of Atrial Fibrillation
Current Medicinal Chemistry Paliperidone Use in the Elderly
Current Drug Safety The Role of Fibroblast Growth Factors in Tumor Growth
Current Cancer Drug Targets Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors
Current Pharmaceutical Design siRNA Silencing of Gene Expression in Trabecular Meshwork: RhoA siRNA Reduces IOP in Mice
Current Molecular Medicine Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Upper Airway Resistance Syndrome
Current Respiratory Medicine Reviews